Legal & General Group’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $474M | Buy |
759,971
+27,917
| +4% | +$19M | 0.1% | 184 |
|
|
2026
Q1 | $566M | Sell |
732,054
-10,973
| -1% | -$8.4M | 0.13% | 143 |
|
|
2025
Q4 | $574M | Sell |
743,027
-27,332
| -4% | -$18.6M | 0.13% | 143 |
|
|
2025
Q3 | $433M | Buy |
770,359
+30,778
| +4% | +$17.4M | 0.1% | 202 |
|
|
2025
Q2 | $388M | Sell |
739,581
-7,452
| -1% | -$4.16M | 0.1% | 209 |
|
|
2025
Q1 | $474M | Sell |
747,033
-30,444
| -4% | -$20.9M | 0.13% | 160 |
|
|
2024
Q4 | $554M | Sell |
777,477
-7,617
| -1% | -$6.39M | 0.15% | 123 |
|
|
2024
Q3 | $825M | Buy |
785,094
+1,301
| +0.2% | +$1.45M | 0.22% | 84 |
|
|
2024
Q2 | $824M | Sell |
783,793
-35,489
| -4% | -$34.4M | 0.23% | 75 |
|
|
2024
Q1 | $789M | Sell |
819,282
-7,406
| -0.9% | -$7.04M | 0.23% | 83 |
|
|
2023
Q4 | $726M | Buy |
826,688
+6,480
| +0.8% | +$5.34M | 0.23% | 84 |
|
|
2023
Q3 | $675M | Sell |
820,208
-26,921
| -3% | -$21.2M | 0.24% | 80 |
|
|
2023
Q2 | $609M | Sell |
847,129
-1,998
| -0.2% | -$1.54M | 0.2% | 103 |
|
|
2023
Q1 | $698M | Buy |
849,127
+17,758
| +2% | +$13.4M | 0.25% | 80 |
|
|
2022
Q4 | $600M | Sell |
831,369
-41,616
| -5% | -$30.7M | 0.23% | 95 |
|
|
2022
Q3 | $601M | Sell |
872,985
-10,302
| -1% | -$6.48M | 0.23% | 89 |
|
|
2022
Q2 | $522M | Buy |
883,287
+75,391
| +9% | +$49M | 0.18% | 110 |
|
|
2022
Q1 | $564M | Buy |
807,896
+57,387
| +8% | +$36.3M | 0.17% | 115 |
|
|
2021
Q4 | $474M | Sell |
750,509
-15,609
| -2% | -$9.6M | 0.14% | 146 |
|
|
2021
Q3 | $464M | Buy |
766,118
+21,066
| +3% | +$13.1M | 0.15% | 136 |
|
|
2021
Q2 | $416M | Buy |
745,052
+36,408
| +5% | +$18.4M | 0.14% | 153 |
|
|
2021
Q1 | $335M | Sell |
708,644
-14,582
| -2% | -$7.1M | 0.12% | 187 |
|
|
2020
Q4 | $349M | Buy |
723,226
+39,979
| +6% | +$21.6M | 0.14% | 158 |
|
|
2020
Q3 | $382M | Sell |
683,247
-9,181
| -1% | -$5.57M | 0.17% | 125 |
|
|
2020
Q2 | $432M | Buy |
692,428
+157,929
| +30% | +$89.6M | 0.21% | 94 |
|
|
2020
Q1 | $261M | Buy |
534,499
+12,205
| +2% | +$5.03M | 0.15% | 152 |
|
|
2019
Q4 | $196M | Buy |
522,294
+21,108
| +4% | +$7.1M | 0.09% | 243 |
|
|
2019
Q3 | $139M | Buy |
501,186
+7,319
| +1% | +$2.17M | 0.07% | 300 |
|
|
2019
Q2 | $155M | Buy |
493,867
+15,410
| +3% | +$5.13M | 0.08% | 276 |
|
|
2019
Q1 | $196M | Buy |
478,457
+93,957
| +24% | +$38.7M | 0.11% | 212 |
|
|
2018
Q4 | $144M | Buy |
384,500
+24,498
| +7% | +$8.97M | 0.11% | 215 |
|
|
2018
Q3 | $145M | Buy |
360,002
+8,792
| +3% | +$3.35M | 0.1% | 222 |
|
|
2018
Q2 | $121M | Sell |
351,210
-13,767
| -4% | -$4.31M | 0.09% | 245 |
|
|
2018
Q1 | $126M | Buy |
364,977
+3,437
| +1% | +$1.2M | 0.1% | 244 |
|
|
2017
Q4 | $136M | Sell |
361,540
-9,570
| -3% | -$3.88M | 0.1% | 239 |
|
|
2017
Q3 | $166M | Buy |
371,110
+2,729
| +0.7% | +$1.3M | 0.12% | 195 |
|
|
2017
Q2 | $181M | Buy |
368,381
+8,060
| +2% | +$3.53M | 0.15% | 174 |
|
|
2017
Q1 | $140M | Buy |
360,321
+16,117
| +5% | +$5.97M | 0.12% | 204 |
|
|
2016
Q4 | $126M | Buy |
344,204
+2,207
| +0.6% | +$839K | 0.12% | 203 |
|
|
2016
Q3 | $137M | Buy |
341,997
+4,324
| +1% | +$1.73M | 0.14% | 173 |
|
|
2016
Q2 | $118M | Buy |
337,673
+1,590
| +0.5% | +$612K | 0.12% | 195 |
|
|
2016
Q1 | $121M | Sell |
336,083
-5,709
| -2% | -$2.35M | 0.13% | 176 |
|
|
2015
Q4 | $186M | Buy |
341,792
+25,766
| +8% | +$14M | 0.21% | 108 |
|
|
2015
Q3 | $147M | Buy |
316,026
+10,886
| +4% | +$5.85M | 0.18% | 136 |
|
|
2015
Q2 | $156M | Buy |
305,140
+2,062
| +0.7% | +$1.01M | 0.18% | 132 |
|
|
2015
Q1 | $137M | Sell |
303,078
-55
| -0% | -$23.3K | 0.16% | 146 |
|
|
2014
Q4 | $124M | Sell |
303,133
-2,805
| -0.9% | -$1.1M | 0.15% | 167 |
|
|
2014
Q3 | $110M | Sell |
305,938
-15,504
| -5% | -$5.2M | 0.13% | 184 |
|
|
2014
Q2 | $90.8M | Buy |
321,442
+3,032
| +1% | +$899K | 0.11% | 232 |
|
|
2014
Q1 | $95.6M | Buy |
318,410
+4,713
| +2% | +$1.45M | 0.12% | 210 |
|
|
2013
Q4 | $86.3M | Buy |
313,697
+2,275
| +0.7% | +$654K | 0.1% | 224 |
|
|
2013
Q3 | $97.4M | Buy |
311,422
+13,718
| +5% | +$3.61M | 0.13% | 188 |
|
|
2013
Q2 | $66.9M | Buy |
+297,704
| New | +$69.3M | 0.09% | 252 |
|
Other funds holding REGN
Legal & General Group's REGN Position: Q2 2026 in Review
Legal & General Group increased its Regeneron Pharmaceuticals (REGN) stake by 3.8% in Q2 2026, buying an estimated $19M and bringing the position to 759,971 shares worth $474M. The position accounts for 0.1% of the portfolio, ranked #184.
Legal & General Group first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $825M in Q3 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Legal & General Group held 759,971 shares of Regeneron Pharmaceuticals worth $474M as of Q2 2026.
- Legal & General Group bought 27,917 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $19M.
- Regeneron Pharmaceuticals made up 0.1% of Legal & General Group's portfolio in Q2 2026, its #184 holding.
- Legal & General Group first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Legal & General Group's Regeneron Pharmaceuticals position peaked at $825M in Q3 2024.
- 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.